首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1356527

非侵入性癌症診斷市場報告：2030 年趨勢、預測與競爭分析

Non-Invasive Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日期: 2023年09月01日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

非侵入性癌症診斷的趨勢和預測

預計到 2030 年，全球非侵入性癌症診斷市場將達到 1,992 億美元，2024 年至 2030 年年複合成長率為 6.8%。該市場的主要促進因素是人們對慢性癌症的日益關注、先進的基於生物標記的檢測方法的引入以及政府支持的促進非侵入性診斷測試使用的舉措。由於固體癌、血癌、肺癌和乳癌市場的商機，全球非侵入性癌症診斷市場的未來充滿希望。

非侵入性癌症診斷市場洞察

根據Lucintel的預測，臨床化學由於其高靈敏度、低成本和廣泛可用性等各種優勢，預計將在預測期內實現最高成長。
由於全球乳癌患者數量不斷增加，乳癌仍然是最大的部分。
由於其發達的醫療基礎設施、癌症相關患者數量的增加以及主要企業的存在，預計北美在預測期內將出現最高的成長。

本報告回答了 11 個關鍵問題：

Q.1. 細分市場中最有前途和高成長的機會是什麼？
Q.2.哪個細分市場將以更快的速度成長？為什麼？
Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
Q.4. 影響市場動態的主要要素有哪些？市場的主要挑戰和商業風險是什麼？
Q.5. 這個市場的商業風險和競爭威脅是什麼？
Q.6.這個市場有哪些新趨勢？為什麼？
Q.7.市場客戶需求有何改變？
Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
Q.10. 該市場上的競爭產品有哪些，由於材料或產品替代導致市場佔有率下降的威脅有多大？
Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

宏觀經濟趨勢（2018-2023）與預測（2024-2030）
全球非侵入性癌症診斷市場趨勢（2018-2023）與預測（2024-2030）
按治療藥物分類的全球非侵入性癌症診斷市場
- 固態腫瘤
- 血癌
- 肺癌
- 乳癌
- 其他
按技術分類的全球非侵入性癌症診斷市場
- 臨床化學
- 免疫化學
- 分子診斷
- 其他

第4章 2018-2030年分地區市場趨勢及預測分析

全球非侵入性癌症診斷市場（按地區）
北美非侵入性癌症診斷市場
歐洲非侵入性癌症診斷市場
亞太非侵入性癌症診斷市場
其他區域非侵入性癌症診斷市場

第5章競爭分析

產品系列分析
營運整合
波特五力分析

第6章成長機會與策略分析

成長機會分析
- 全球非侵入性癌症診斷與治療市場的成長機會
- 全球非侵入性癌症診斷市場的技術成長機會
- 全球非侵入性癌症診斷市場區域成長機會
全球非侵入性癌症診斷市場的新興趨勢
戰略分析
- 新產品開發
- 擴大全球非侵入性癌症診斷市場的能力
- 全球非侵入性癌症診斷市場的合併、收購和合資企業
- 認證和許可

第7章主要企業概況

Precision Therapeutics
A&G Pharmaceutical
Affymetrix
AVIVA Biosciences
BIOVIEW
Laboratory Corporation of America
Quest Diagnostics Incorporated Cancer Genetics
Digene
Gen-Probe
IVDiagnostics

簡介目錄

Non-Invasive Cancer Diagnostic Trends and Forecast

The future of the global non-invasive cancer diagnostic market looks promising with opportunities in the solid tumors, blood cancer, lung cancer, and breast cancer markets. The global non-invasive cancer diagnostic market is expected to reach an estimated $199.2 billion by 2030 with a CAGR of 6.8% from 2024 to 2030. The major drivers for this market are rising concerns of chronic cancer, introduction of advanced bio marker based detection methods,and supportive government initiative to promote the use of non-invasive diagnostic test.

A more than 150-page report is developed to help in your business decisions.

Non-Invasive Cancer Diagnostic by Segment

The study includes a forecast for the global non-invasive cancer diagnostic by therapeutics, technology, end use industry, technology, and region.

Non-Invasive Cancer Diagnostic Market by Therapeutics [Shipment Analysis by Value from 2018 to 2030]:

Solid Tumors
Blood Cancer
Lung Cancer
Breast Cancer
Others

Non-Invasive Cancer Diagnostic Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

Clinical Chemistry
Immunochemistry
Molecular Diagnostics
Others

Non-Invasive Cancer Diagnostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

North America
Europe
Asia Pacific
The Rest of the World

List of Non-Invasive Cancer Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies non-invasive cancer diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the non-invasive cancer diagnostic companies profiled in this report include-

Precision Therapeutics
A&G Pharmaceutical
Affymetrix
AVIVA Biosciences
BIOVIEW
Laboratory Corporation Of America
Quest Diagnostics Incorporated Cancer Genetics
Digene
Gen-Probe
IVDiagnostics

Non-Invasive Cancer Diagnostic Market Insights

Lucintel forecast that clinical chemistry is expected to witness highest growth over the forecast period due to its various advantages, including highly sensitive, low cost, and widespread availibility.

Breast cancer will remain the largest segment due to increasing number of breast cancer patients around the world.

North America is expected to witness highest growth over the forecast period due to existence of well-established health infrastructure, growing prevalence of cancer related cases among people, and presence of key players in the region.

Features of the Global Non-Invasive Cancer Diagnostic Market

Market Size Estimates: Non-invasive cancer diagnostic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Non-invasive cancer diagnostic market size by therapeutics, technology, and region. in terms of value ($B).

Regional Analysis: Non-invasive cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapeutics, technology, and region.s for the non-invasive cancer diagnostic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the non-invasive cancer diagnostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the non-invasive cancer diagnostic market size?

Answer: The global non-invasive cancer diagnostic market is expected to reach an estimated $199.2 billion by 2030.

Q.2. What is the growth forecast for non-invasive cancer diagnostic market?

Answer: The global non-invasive cancer diagnostic market is expected to grow with a CAGR of 6.8% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the non-invasive cancer diagnostic market?

Answer: The major drivers for this market are rising concerns of chronic cancer, introduction of advanced bio marker based detection methods, and supportive government initiative to promote the use of non-invasive diagnostic test.

Q.4. What are the major segments for non-invasive cancer diagnostic market?

Answer: The future of the non-invasive cancer diagnostic market looks promising with opportunities in the solid tumors, blood cancer, lung cancer, and breast cancer markets.

Q.5. Who are the key non-invasive cancer diagnostic market companies?

Answer: Some of the key non-invasive cancer diagnostic companies are as follows:

Precision Therapeutics
A&G Pharmaceutical
Affymetrix
AVIVA Biosciences
BIOVIEW
Laboratory Corporation of America
Quest Diagnostics Incorporated Cancer Genetics
Digene
Gen-Probe
IVDiagnostics

Q.6. Which non-invasive cancer diagnostic market segment will be the largest in future?

Answer: Lucintel forecast that clinical chemistry is expected to witness highest growth over the forecast period due to its various advantages, including highly sensitive, low cost, and widespread availibility.

Q.7. In non-invasive cancer diagnostic market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to existence of well-established health infrastructure, growing prevalence of cancer related cases among people, and presence of key players in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the non-invasive cancer diagnostic market by therapeutics (solid tumors, blood cancer, lung cancer,breast cancer, and others), technology (clinical chemistry, immunochemistry, molecular diagnostics, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Global Non-Invasive Cancer Diagnostic Market : Market Dynamics

2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Non-Invasive Cancer Diagnostic Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Non-Invasive Cancer Diagnostic Market by Therapeutics
- 3.3.1: Solid Tumors
- 3.3.2: Blood Cancer
- 3.3.3: Lung Cancer
- 3.3.4: Breast Cancer
- 3.3.5: Others
3.4: Global Non-Invasive Cancer Diagnostic Market by Technology
- 3.4.1: Clinical Chemistry
- 3.4.2: Immunochemistry
- 3.4.3: Molecular Diagnostics
- 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

4.1: Global Non-Invasive Cancer Diagnostic Market by Region
4.2: North American Non-Invasive Cancer Diagnostic Market
- 4.2.1: North American Non-Invasive Cancer Diagnostic Market by Therapeutics : Solid tumors, Blood cancer, Lung Cancer,Breast Cancer,and Others
- 4.2.2: North American Non-Invasive Cancer Diagnostic Market by Technology:Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others
4.3: European Non-Invasive Cancer Diagnostic Market
- 4.3.1: European Non-Invasive Cancer Diagnostic Market by Therapeutics : Solid tumors, Blood cancer, Lung Cancer,Breast Cancer,and Others
- 4.3.2: European Non-Invasive Cancer Diagnostic Market by Technology: Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others
4.4: APAC Non-Invasive Cancer Diagnostic Market
- 4.4.1: APAC Non-Invasive Cancer Diagnostic Market by Therapeutics :Solid tumors, Blood cancer, Lung Cancer,Breast Cancer,and Others
- 4.4.2: APAC Non-Invasive Cancer Diagnostic Market by Technology:Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others
4.5: ROW Non-Invasive Cancer Diagnostic Market
- 4.5.1: ROW Non-Invasive Cancer Diagnostic Market by Therapeutics : Solid tumors, Blood cancer, Lung Cancer,Breast Cancer,and Others
- 4.5.2: ROW Non-Invasive Cancer Diagnostic Market by Technology: Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others

5. Competitor Analysis

5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global Non-Invasive Cancer Diagnostic Market by Therapeutics
- 6.1.2: Growth Opportunities for the Global Non-Invasive Cancer Diagnostic Market by Technology
- 6.1.3: Growth Opportunities for the Global Non-Invasive Cancer Diagnostic Market Region
6.2: Emerging Trends in the Global Non-Invasive Cancer Diagnostic Market
6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global Non-Invasive Cancer Diagnostic Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Non-Invasive Cancer Diagnostic Market
- 6.3.4: Certification and Licensing